Deal Watch: NewAmsterdam To Take On Amgen’s Stalled CETP Inhibitor
Executive Summary
New company licenses obicetrapib from Amgen after previous companies’ setbacks in CETP class and works with FDA on a Phase III protocol. BMS buys protein-engineering specialist Forbius.
You may also be interested in...
Yumanity Merges With Proteostasis To Accelerate Parkinson’s Therapy
Yumanity goes public by merging with Proteostasis; it is accelerating its Parkinson’s program because of mouse model data showing disease-modifying potential. Proteostasis will out-license its CF assets.
$9m From ‘Transformational Acquisitions’ Keeps Advanz Growing In Second Quarter
Advanz added $5.5m of revenue from its recently acquired alprostadil products and $3.3m from Correvio in the second quarter of 2020. After seeking approval for seven medicines during the second quarter alone, the company plans to launch another 17 products in 2020.
Takeda Confirms $2.3bn Deal With Blackstone For Japan Consumer Business
In a widely anticipated move, Takeda has confirmed the sale of its consumer healthcare business in Japan, to the US private equity group Blackstone.
Need a specific report? 1000+ reports available
Buy Reports